Literature DB >> 12932587

Is aortic stenosis a preventable disease?

Kwan-Leung Chan1.   

Abstract

Aortic stenosis (AS) is the most common valvular disease requiring valve replacement. Its prevalence increases with age. When the severity of AS is only mild to moderate, it is well tolerated. When it becomes severe, AS confers significant morbidity and mortality. Adverse events can be avoided if it is possible to prevent or retard the progression from mild or moderate AS to severe AS. Progression of AS parallels the progression of sclerotic changes involving the aortic valve, which share histological and immunochemical similarities with the process of atherosclerosis. Far from being just a degenerative process, the development of AS is a complex and highly regulated process with a number of modifiable factors. One of the key factors appears to be lipoproteins, which are intimately involved in several pathways crucial to the development of AS. The importance of lipoproteins is further supported by epidemiological and clinical studies showing a strong association between lipoproteins and AS. The time has come to initiate prospective studies to assess the effect of cholesterol lowering on the progression of AS.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12932587     DOI: 10.1016/s0735-1097(03)00786-1

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  17 in total

1.  A theory for water and macromolecular transport in the pulmonary artery wall with a detailed comparison to the aorta.

Authors:  Zhongqing Zeng; Kung-Ming Jan; David S Rumschitzki
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-12-23       Impact factor: 4.733

2.  Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients.

Authors:  Kana Wakabayashi; Takeshi Tsujino; Yoshiro Naito; Akira Ezumi; Masaaki Lee-Kawabata; Shinji Nakao; Akiko Goda; Yasushi Sakata; Kazuhiro Yamamoto; Takashi Daimon; Tohru Masuyama
Journal:  Heart Vessels       Date:  2010-11-10       Impact factor: 2.037

3.  Tissue resident C reactive protein in degenerative aortic valves: correlation with serum C reactive protein concentrations and modification by statins.

Authors:  D Skowasch; S Schrempf; C J Preusse; J A Likungu; A Welz; B Lüderitz; G Bauriedel
Journal:  Heart       Date:  2005-09-13       Impact factor: 5.994

4.  Is it time for medical therapy for aortic valve disease?

Authors:  Nalini M Rajamannan
Journal:  Expert Rev Cardiovasc Ther       Date:  2004-11

Review 5.  Degenerative aortic stenosis.

Authors:  Radhakrishnan Ramaraj; Vincent L Sorrell
Journal:  BMJ       Date:  2008-03-08

6.  Assessment of risk factors for developing incident aortic stenosis: the Tromsø Study.

Authors:  Gry Wisthus Eveborn; Henrik Schirmer; Per Lunde; Geir Heggelund; John-Bjarne Hansen; Knut Rasmussen
Journal:  Eur J Epidemiol       Date:  2014-07-15       Impact factor: 8.082

7.  Ethnic differences in aortic valve thickness and related clinical factors.

Authors:  Yukiko Sashida; Carlos J Rodriguez; Bernadette Boden-Albala; Zhezhen Jin; Mitchell S V Elkind; Rui Liu; Tatjana Rundek; Ralph L Sacco; Marco R DiTullio; Shunichi Homma
Journal:  Am Heart J       Date:  2010-04       Impact factor: 4.749

Review 8.  Lipid lowering and aortic valve disease.

Authors:  Anders G Olsson
Journal:  Curr Atheroscler Rep       Date:  2009-09       Impact factor: 5.113

9.  Linking soluble vascular adhesion molecule-1 level to calcific aortic stenosis in patients with coronary artery disease.

Authors:  Katerina Linhartova; Gabriela Sterbakova; Jaroslav Racek; Roman Cerbak; Karolina Porazikova; Richard Rokyta
Journal:  Exp Clin Cardiol       Date:  2009

10.  Management of asymptomatic severe aortic stenosis.

Authors:  Robert L Stewart; Kwan L Chan
Journal:  Curr Cardiol Rev       Date:  2009-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.